Skip to Main Content
Table 2—

Change from baseline after 3 months of treatment

MetforminPlaceboP
n 14 13 — 
Δ SI (× 10−4 min−1 · μU−1 · ml−12.6 (CI 1.0–4.1) 2.5 (CI 1.9–2.9) 0.26 
Δ HbA1c (%) –0.3 ± 0.7 0.3 ± 0.7* 0.03 
Δ fasting glucose (mmol/l) –0.9 ± 3.8 –0.5 ± 3.2* 0.04 
Δ insulin dose (units · kg−1 · day−1–0.14 ± 0.1 0.02 ± 0.2* 0.01 
Δ BMI (kg/m2–0.05 ± 1.0 0.2 ± 0.5 0.35 
MetforminPlaceboP
n 14 13 — 
Δ SI (× 10−4 min−1 · μU−1 · ml−12.6 (CI 1.0–4.1) 2.5 (CI 1.9–2.9) 0.26 
Δ HbA1c (%) –0.3 ± 0.7 0.3 ± 0.7* 0.03 
Δ fasting glucose (mmol/l) –0.9 ± 3.8 –0.5 ± 3.2* 0.04 
Δ insulin dose (units · kg−1 · day−1–0.14 ± 0.1 0.02 ± 0.2* 0.01 
Δ BMI (kg/m2–0.05 ± 1.0 0.2 ± 0.5 0.35 

Data are means ± SD, except for SI, which is expressed as geometric mean and 95% CI.

*

P < 0.05 vs. metformin group.

Close Modal

or Create an Account

Close Modal
Close Modal